MXPA02012033A - Derivados de 2-aminocarbonil-9h-purina. - Google Patents
Derivados de 2-aminocarbonil-9h-purina.Info
- Publication number
- MXPA02012033A MXPA02012033A MXPA02012033A MXPA02012033A MXPA02012033A MX PA02012033 A MXPA02012033 A MX PA02012033A MX PA02012033 A MXPA02012033 A MX PA02012033A MX PA02012033 A MXPA02012033 A MX PA02012033A MX PA02012033 A MXPA02012033 A MX PA02012033A
- Authority
- MX
- Mexico
- Prior art keywords
- aminocarbonyl
- purine derivatives
- compounds
- preparation
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula: (Ver formula) y sus sales y solvatos farmaceuticamente aceptables, y a procedimientos para la preparacion de, compuestos intermedios utilizados en la preparacion de, composiciones que contienen dichos derivados, y sus usos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0014048A GB0014048D0 (en) | 2000-06-06 | 2000-06-06 | Purine derivatives |
GB0018246A GB0018246D0 (en) | 2000-06-06 | 2000-07-25 | Purine derivatives |
GB0024920A GB0024920D0 (en) | 2000-06-06 | 2000-10-11 | Purine derivatives |
PCT/IB2001/000973 WO2001094368A1 (en) | 2000-06-06 | 2001-06-05 | 2-aminocarbonyl-9h-purine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012033A true MXPA02012033A (es) | 2003-04-25 |
Family
ID=27255754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012033A MXPA02012033A (es) | 2000-06-06 | 2001-06-05 | Derivados de 2-aminocarbonil-9h-purina. |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP1292604B1 (es) |
JP (2) | JP4129176B2 (es) |
KR (1) | KR100484704B1 (es) |
CN (1) | CN1249074C (es) |
AR (1) | AR030289A1 (es) |
AT (1) | ATE431356T1 (es) |
AU (2) | AU2001260537B2 (es) |
BG (1) | BG107216A (es) |
BR (1) | BR0111263A (es) |
CA (1) | CA2414018C (es) |
CU (1) | CU23240B7 (es) |
CZ (1) | CZ20023875A3 (es) |
DE (1) | DE60138702D1 (es) |
DK (1) | DK1292604T3 (es) |
DZ (1) | DZ3439A1 (es) |
EA (1) | EA004983B1 (es) |
EE (1) | EE200200678A (es) |
ES (1) | ES2324816T3 (es) |
GC (1) | GC0000287A (es) |
HK (2) | HK1054042A1 (es) |
HR (1) | HRP20020960A2 (es) |
HU (1) | HUP0301330A3 (es) |
IL (2) | IL152783A0 (es) |
IS (1) | IS6599A (es) |
MA (1) | MA26910A1 (es) |
MX (1) | MXPA02012033A (es) |
NO (1) | NO324426B1 (es) |
NZ (1) | NZ522184A (es) |
OA (1) | OA12279A (es) |
PA (1) | PA8518801A1 (es) |
PL (1) | PL360435A1 (es) |
SK (1) | SK16752002A3 (es) |
TW (1) | TWI227240B (es) |
WO (1) | WO2001094368A1 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
US20030013675A1 (en) * | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
NZ556354A (en) | 2001-10-01 | 2008-10-31 | Univ Virginia | 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof |
GB0129270D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
GB0129273D0 (en) | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
JP2006515829A (ja) * | 2002-04-10 | 2006-06-08 | ユニバーシティ オブ バージニア パテント ファウンデーション | 炎症性疾病の処置のための、a2aアデノシン受容体アゴニストの使用 |
US7067509B2 (en) | 2003-03-07 | 2006-06-27 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
US20060178403A1 (en) * | 2003-03-07 | 2006-08-10 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
JP2007509180A (ja) | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
US7335648B2 (en) | 2003-10-21 | 2008-02-26 | Inspire Pharmaceuticals, Inc. | Non-nucleotide composition and method for inhibiting platelet aggregation |
US7749981B2 (en) | 2003-10-21 | 2010-07-06 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound |
JP2007514647A (ja) | 2003-10-21 | 2007-06-07 | インスパイアー ファーマシューティカルズ,インコーポレイティド | テトラヒドロ−フロ[3,4−d]ジオキソール化合物並びに血小板凝集を阻害する組成物及び方法 |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
WO2006023272A1 (en) | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
EP1778712B1 (en) | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
US7932376B2 (en) | 2005-05-05 | 2011-04-26 | Inspire Pharmaceuticals, Inc. | Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Il13に対するヒト抗体および治療的使用 |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
BRPI0906838A2 (pt) | 2008-01-11 | 2015-07-14 | Novartis Ag | Pirimidinas como inibidores de quinase |
GEP20135957B (en) * | 2008-06-19 | 2013-11-11 | Takeda Pharmaceuticals Co | Heterocyclic compound and usage thereof |
US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
EP2435462A1 (en) | 2009-05-29 | 2012-04-04 | Pfizer Limited | Novel glucocorticoid receptor agonists |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
IN2012DN01453A (es) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Trk阻害剤としてのピラゾロ[1,5−a]ピリジン |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
ES2894830T3 (es) | 2012-04-03 | 2022-02-16 | Novartis Ag | Productos combinados con inhibidores de tirosina·cinasa y su uso |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
ES2831416T3 (es) | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2347512C (en) * | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
-
2001
- 2001-05-31 TW TW090113146A patent/TWI227240B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102656A patent/AR030289A1/es active IP Right Grant
- 2001-06-05 WO PCT/IB2001/000973 patent/WO2001094368A1/en active Application Filing
- 2001-06-05 ES ES01934242T patent/ES2324816T3/es not_active Expired - Lifetime
- 2001-06-05 CZ CZ20023875A patent/CZ20023875A3/cs unknown
- 2001-06-05 DK DK01934242T patent/DK1292604T3/da active
- 2001-06-05 GC GCP20011415 patent/GC0000287A/en active
- 2001-06-05 KR KR10-2002-7016606A patent/KR100484704B1/ko not_active IP Right Cessation
- 2001-06-05 EE EEP200200678A patent/EE200200678A/xx unknown
- 2001-06-05 BR BR0111263-5A patent/BR0111263A/pt not_active IP Right Cessation
- 2001-06-05 CA CA002414018A patent/CA2414018C/en not_active Expired - Fee Related
- 2001-06-05 CN CNB018108024A patent/CN1249074C/zh not_active Expired - Fee Related
- 2001-06-05 DZ DZ013439A patent/DZ3439A1/fr active
- 2001-06-05 AT AT01934242T patent/ATE431356T1/de not_active IP Right Cessation
- 2001-06-05 OA OA1200200363A patent/OA12279A/en unknown
- 2001-06-05 EP EP01934242A patent/EP1292604B1/en not_active Expired - Lifetime
- 2001-06-05 IL IL15278301A patent/IL152783A0/xx active IP Right Grant
- 2001-06-05 EA EA200201179A patent/EA004983B1/ru not_active IP Right Cessation
- 2001-06-05 SK SK1675-2002A patent/SK16752002A3/sk unknown
- 2001-06-05 DE DE60138702T patent/DE60138702D1/de not_active Expired - Lifetime
- 2001-06-05 PL PL36043501A patent/PL360435A1/xx not_active Application Discontinuation
- 2001-06-05 NZ NZ522184A patent/NZ522184A/en unknown
- 2001-06-05 JP JP2002501916A patent/JP4129176B2/ja not_active Expired - Fee Related
- 2001-06-05 MX MXPA02012033A patent/MXPA02012033A/es active IP Right Grant
- 2001-06-05 AU AU2001260537A patent/AU2001260537B2/en not_active Ceased
- 2001-06-05 AU AU6053701A patent/AU6053701A/xx active Pending
- 2001-06-05 HU HU0301330A patent/HUP0301330A3/hu unknown
- 2001-06-06 PA PA20018518801A patent/PA8518801A1/es unknown
-
2002
- 2002-10-23 BG BG107216A patent/BG107216A/bg unknown
- 2002-10-29 IS IS6599A patent/IS6599A/is unknown
- 2002-11-26 CU CU20020281A patent/CU23240B7/es not_active IP Right Cessation
- 2002-12-02 MA MA26930A patent/MA26910A1/fr unknown
- 2002-12-04 NO NO20025821A patent/NO324426B1/no not_active IP Right Cessation
- 2002-12-05 HR HR20020960A patent/HRP20020960A2/hr not_active Application Discontinuation
-
2003
- 2003-09-05 HK HK03106312A patent/HK1054042A1/xx not_active IP Right Cessation
-
2006
- 2006-09-05 HK HK06109837A patent/HK1089447A1/xx not_active IP Right Cessation
-
2007
- 2007-06-21 IL IL184144A patent/IL184144A/en not_active IP Right Cessation
-
2008
- 2008-01-15 JP JP2008005804A patent/JP2008150383A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
BE2017C018I2 (es) | ||
DE60112609D1 (en) | Pyrazolopyridine | |
NL350075I2 (es) | ||
BG107171A (en) | Purine derivatives | |
HK1048990A1 (en) | Novel compounds. | |
GB0114286D0 (en) | Nucleoside Derivatives | |
AP2001002204A0 (en) | Pyrazole derivatives. | |
BG106569A (en) | Purine derivatives | |
PL366198A1 (en) | Novel compounds | |
IL142649A0 (en) | Azole derivatives | |
IL150986A0 (en) | 1,2,3,4,- tetrahydroisoquinoline derivatives | |
MXPA03005464A (es) | Agentes antivirales. | |
BG106567A (en) | Purine derivatives | |
BG106289A (en) | Purine derivatives | |
MXPA02007942A (es) | Derivados de pirrolopirimidinona, procesos de preparacion y uso. | |
AU2003228770A1 (en) | Substituted pyrazolopyrimidines | |
YU41199A (sh) | Hinoksalindioni | |
DE60112330D1 (en) | Pyrazolopyridinderivate | |
MXPA05012247A (es) | Derivados de bencimidazol nuevos. | |
DE60114640D1 (en) | Antithrombosemittel | |
MXPA02004441A (es) | Derivados de isoxazol como inhibidores de la fosfodiesterasa. | |
AU2002248531A1 (en) | Pyrazolopyriadine derivatives | |
AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
AU2002357740A1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |